Nida data, statistics, and clinical trial support center. September 5, 2022 to september 4, 2027. N01DA-22-2253.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95022D00017
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 29 $33,577,850 obligated
Award facts
- Opportunity
-
- Data, Statistics, and Clinical Trial Support Center (DSC6) Pre-Solicitation · 75N95022D00009 · Posted Nov 10, 2021
- Combined order value
- $33,577,850 Current and potential, with all options
- Last date to order 83% complete
- IDV ceiling 76% used
- $44,313,082.00
- Maximum order
- $44,313,082.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health, awarded a single-award Indefinite Delivery Contract valued at $44.3 million to The Emmes Company, LLC on September 5, 2022, with a five-year performance period extending through September 4, 2027. This IDV contract (N01DA-22-2253) establishes a Data, Statistics, and Clinical Trial Support Center to provide comprehensive research support services to the National Drug Abuse Treatment Clinical Trials Network. The contracted services encompass data management, statistical analysis, document management, electronic data capture systems, quality assurance monitoring, and clinical trial coordination. The Emmes Company, a global clinical research organization headquartered in Rockville, Maryland, will leverage its expertise in biostatistical analysis, clinical trial design, protocol monitoring, and regulatory support to advance NIDA's portfolio of substance abuse treatment research, with particular emphasis on the expanding opioid treatment trials. The work is performed at facilities located in Potomac and Rockville, Maryland, under cost-plus-fixed-fee and cost-plus-award-fee pricing structures.
Through this IDV vehicle, NIDA has exercised 26 delivery orders totaling approximately $29.5 million as of May 2025, supporting diverse clinical research initiatives spanning opioid use disorder, stimulant use disorders, cocaine use disorder, and related conditions. Representative task orders include the Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders clinical trial ($2.1 million), the Ketamine for Methamphetamine Use Disorder Study ($1.9 million), and the DSC Management and Support initiatives ($2.3 million). Additional task orders support specialized programs such as culturally centered medication-assisted treatment for American Indian/Alaska Native populations, emergency department-initiated buprenorphine interventions, rural expansion of medication treatment, and the HEAL (Helping to End Addiction Long-Term) initiative. Each delivery order is tailored to specific clinical trial requirements while maintaining the flexibility inherent to the IDV structure, enabling NIDA to rapidly procure specialized research support services aligned with evolving programmatic priorities and funding availability.
Task orders
Show all 29
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95022D00017?
75N95022D00017 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on September 5, 2022.
How much is contract 75N95022D00017 worth?
Orders under 75N95022D00017 have obligated $33,577,850. 75N95022D00017's own ceiling is $44,313,082. A single order can be worth up to $44,313,082.
How many orders have been placed under contract 75N95022D00017?
29 orders have been placed under 75N95022D00017, the latest on April 29, 2026.
Who can order from contract 75N95022D00017?
75N95022D00017 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95022D00017 competed?
The extent of competition for 75N95022D00017 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV